Form D · Biotechnology
Arbovax, Inc.
Raleigh, NC · CIK 0001521629
Offering snapshot reported Apr 4, 2014 · SEC filing
- Reported sold
- $1.69M Offering amount: $2.1M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 20, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 4, 2014 | Initial | $1,694,917 | No comparison | 9 | SEC filing |
| May 25, 2011 | Initial | $1,735,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-214915
Source: Form D, filed Apr 4, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Leslie Alexandre | Director |
| Christopher English | Director |
| Herb Hugill | Director |
| Troy Knauss | Director |
| Jonathan Lawrie | Director |
| Jeremy Mario | Director |
| Charlton Owensby | Director |
| Malcolm Thomas | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
617 Hutton Street, Suite 101
Raleigh, NC, 27606-6301
Raleigh, NC, 27606-6301